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doi:10.1016/j.jtcvs.2007.12.013Objective: The extracardiac conduit Fontan procedure has led to improved outcomes.
We performed the procedure in patients weighing less than 10 kg and evaluated its
feasibility.
Methods: Since January 1999, 72 patients weighing less than 20 kg underwent extrac-
ardiac conduit Fontan procedure with polytetrafluoroethylene conduits. The patients
were divided into 2 groups: 36 patients weighing less than 10 kg in group S and 36
weighing more than 10 kg in group L. Mean weight, median age, and median fol-
low-up period in groups S and L were 8.5 6 1.1 and 14.0 6 3.0 kg, 18.9 and 42.0
months, and 29.2 (1.7–79.7) and 42.1 (2.8–94.2) months, respectively. Postopera-
tively, most patients received peritoneal drainage catheters. We reviewed data preca-
theterization and postcatheterization and postoperative course.
Results: Conduit sizes in groups S and L were 17.06 1.3 and 17.96 1.9 mm, respec-
tively (P5 .03). Five patients required fenestrations. There were 2 hospital deaths, 1
in each group, and 2 late deaths in group S. The postoperative course was identical in
both groups, except for median length of stay in the intensive care unit and peritoneal
drainage volume. Group S versus L: ventilator support, 11 versus 7 hours; pleural
drainage, 9 days each; pleural drainage greater than 14 days, 6 versus 5 cases; perito-
neal drainage, 8 versus 7 days; intensive care unit stay, 7 versus 4 days (P5 .01), peri-
toneal drainage volume, 26.1 versus 14.1 mL $ kg $ d21 (P 5 .0007).
Conclusions: The early outcome of the extracardiac conduit Fontan procedure was
satisfactory in patients weighing less than 10 kg. However, the required size of the
conduit remains debatable.
T
he current surgical goal for most patients with a functional single ventricle is
staged palliation culminating in a successful Fontan procedure. Since its intro-
duction in 1971,1 the Fontan procedure has undergone many modifications.
Currently, two modifications are commonly used—the lateral tunnel and extracardiac
conduit Fontan procedures (LTFP and ECFP, respectively).2-4 The ECFP, introduced
in 1990,5 minimizes intratrial flow obstruction caused by intratrial partition. More-
over, the ECFP can be performed as a closed cardiac procedure without hypothermia,
myocardial ischemia, or cardiopulmonary bypass.6 The hemodynamic advantages of
a tubular Fontan pathway have been convincingly demonstrated by hydrodynamic
and computational modeling studies.7,8 However, the ECFP has potential disadvan-
tages related to the use of a prosthetic conduit, including the lack of growth potential,
Fontan pathway obstruction, and thromboembolism. In particular, it is common prac-
tice to delay completion of Fontan circulation until the patient’s body weight exceeds
15 kg to place an adult-sized conduit of at least 20 mm in diameter.9 However, one
final treatment goal in patients with single ventricle physiology is the elimination
of cyanosis. To eliminate cyanosis as early in life as possible, we therefore performed
the ECFP in patients weighing less than 10 kg and evaluated the feasibility of this
strategy.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1145
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DAbbreviations and Acronyms
ECFP 5 extracardiac conduit Fontan procedure
ECMO 5 extracorporeal membrane oxygenation
IVC 5 inferior vena cava
LTFP 5 lateral tunnel Fontan procedure
PTFE 5 polytetrafluoroethylene
Patients and Methods
This study was approved by the ethics committee of Shizuoka
Children’s Hospital, and informed consent was obtained from all pa-
tients’ parents. From January 1997 to November 2006, 72 consecu-
tive ECFPs were performed at Shizuoka Children’s Hospital in
patients weighing less than 20 kg. During the same period, we per-
formed a total of 152 ECFPs. To precisely evaluate the influence of
body weight on the ECFP, we excluded 43 patients who weighed
more than 20 kg, 18 patients who had undergone direct anastomosis
between the inferior vena cava (IVC) and the main pulmonary artery
stump, 18 patients who had undergone the LTFP, and 1 patient who
had undergone an intracardiac conduit Fontan procedure. The remain-
ing 72 patients were divided as follows into 2 equal groups on the ba-
sis of body weight: 36 patients weighing less than 10 kg (group S) and
36 weighing more than 10 kg (group L). Cardiac catheterization was
performed in the midterm postoperative period at approximately
1 year after the operation. Follow-up was complete in all patients.1146 The Journal of Thoracic and Cardiovascular Surgery c MaSurgical Techniques
All the ECFPs were performed via a median sternotomy and with
cardiopulmonary bypass. Aortic crossclamping was used in 41 pa-
tients, including 17 (47%) group S and 24 (67%) group L patients.
In crossclamped patients, myocardial protection was achieved with
antegrade cold crystalloid cardioplegia. In small patients, the pulmo-
nary artery incision was extended into the anterior wall of the supe-
rior vena cava to obtain enough space for anastomosis. As a conduit,
we used polytetrafluoroethylene (PTFE; Gore-Tex; W. L. Gore &
Associates, Inc, Flagstaff, Ariz) of 14 to 20 mm in diameter. Mod-
ified ultrafiltration was used in all patients. Fenestrations were not
initially placed. In patients in whom Fontan pressure greater
than18 mm Hg developed after modified ultrafiltration, a fenestra-
tion was placed by interposing a small PTFE graft 4 or 5 mm in
diameter between the conduit and the atrium.
A total of 69 patients had undergone previous procedures. Newly
developed intrapulmonary artery septation procedures,10 which con-
sist of unilateral cavopulmonary anastomosis, aortopulmonary
shunt, and septation between two blood sources, were applied in
both patient groups to promote growth in small pulmonary arteries.
The following procedures were concomitantly performed in 41
patients (17 group S and 24 group L patients): atrioventricular valve
repair, branch pulmonary artery stenosis repair, atrial septectomy,
main pulmonary artery division, pulmonary vein repair, Damus–
Kaye–Stansel anastomosis, subaortic stenosis repair, and pace-
maker-related procedures (see Table 3).TABLE 1. Preoperative patient profiles and cardiac catheterization data
Group S Group L P value
Age (mo)
Mean 21.0 6 8.7 54.7 6 32.9
Median 18.9 (10.6–45.0) 42.0 (16.9–151.3) ,.0001
Weight (kg)
Mean 8.5 6 1.1 14.0 6 3.0
Median 8.7 (5.7–10.2) 13.9 (10.3–19.8) ,.0001
Anatomic diagnosis
No. % No. %
HLHS 11 31 3 8 .03
Isomerism/heterotaxy 10 28 15 42 .38
Univentricular heart 6 17 7 19 .59
Tricuspid atresia 2 6 2 6 .999
Common atrioventricular canal 1 3 3 8 .33
DORV 1 3 3 8 .33
PA/IVS 2 6 0 0 .16
Other 3 8 3 8
Total 36 36
Preoperative data n n
PA pressure, mean (mm Hg) 13 6 3 31 12 6 2 29 .62
Atrial pressure, mean (mm Hg) 7 6 3 36 7 6 2 36 .25
Room air saturation (%) 85 6 4 33 85 6 5 36 .38
Rp (Wood units) 2.0 6 1.0 24 1.5 6 0.8 32 .06
Ejection fraction (%) 58 6 10 35 57 6 11 34 .42
Nakata index 247 6 122 34 250 6 127 31 .84
HLHS, Hypoplastic left heart syndrome; DORV, double-outlet right ventricle; PA/IVS, pulmonary atresia with intact ventricular septum; PA, pulmonary artery;
Rp, resistance of pulmonary artery.y 2008
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DBilateral pleural drainage tubes were placed in all patients and
removed when a drainage volume of less than 1 mL $ kg $ d21 was
achieved in each tube. Peritoneal drainage tubes were regularly used
to remove peritoneal fluid and to reduce intraperitoneal pressure;
they were removed when a drainage volume of less than 2 mL $
kg $ d21 was achieved. In both patient groups, we routinely admin-
istered 5 mg/kg ticlopidine as antiplatelet therapy. Warfarin was not
used.
Statistics
Data from groups were compared by the unpaired Student t test,
Fisher exact test, or c2 test, as appropriate. Serial data from postop-
erative catheterization were compared by the paired Student t test.
Data are shown as mean 6 standard deviation or median (range).
The Kaplan–Meier method was used to determine the time from
surgery to death or the last follow-up visit.
Results
The preoperative age and body weight of patients in group S
were significantly lower than in group L (Table 1). The num-
ber of patients having the morphologic features of hypoplas-
tic left heart syndrome was higher in group S than in group L
(group S vs group L: 11 vs 3; P5 .03). Half of the patients in
both groups had either hypoplastic left heart syndrome or
heterotaxy syndrome. All patients underwent cardiac cathe-
terization before ECFP. The mean values of the variables
measured at catheterization were essentially identical in
both groups. Pulmonary artery resistance was slightly higher
in group S than in group L, but without significant difference
(Table 1).
Only 3 of the 72 patients underwent the ECFP as a primary
procedure. Further, 10 patients underwent ECFP without pre-
vious cavopulmonary connection. The remaining 59 patients
had an interim cavopulmonary connection as a staging proce-
dure, including 14 patients with intrapulmonary artery septa-
tion, 1 patient with a hemi-Fontan procedure, and 1 patient
with a Kawashima procedure (Table 2). Other operations
conducted previously are listed in Table 2. A significantly
greater number of group S patients had previously undergone
the Norwood procedures (36% vs 8%), whereas group L pa-
tients had more frequently undergone isolated aortopulmo-
nary or ventricular–pulmonary shunt procedures. Neither
the mean cardiopulmonary bypass time nor the mean cross-
clamp time differed between the 2 groups. Fenestrations
were placed in 3 group S and 2 group L patients. The size
of the conduit used in group S was significantly smaller than
that used in group L (17.0 6 1.3 mm vs 17.9 6 1.9 mm;
P 5 .03) (Table 3). However, we have recently used 18-mm
conduits in an increasingnumberofgroupSpatients (Figure1).
Early Outcome
The overall operative mortality was 2 (2.8%) of 72 patients.
One group S patient with heterotaxy syndrome who had con-
comitantly undergone atrioventricular valve replacement diedThe Journal of Thorof contractile dysfunction resulting from supraventricular
tachycardia. A group L patient who had heterotaxy syndrome
without fenestration died of cerebral embolism. Extracorpo-
real membrane oxygenation (ECMO) was used in 2 group S
patients. A patient with pulmonary atresia with intact ventric-
ular septum, who had sinusoidal communication had hemo-
dynamic instability owing to coronary malperfusion. The
patient was supported by ECMO for 3 days and survived. An-
other patient with the heterotaxy syndrome and pulmonary
vein stenosis, who had previously undergone repair of total
anomalous pulmonary venous connection followed by atrio-
ventricular valve repair as a concomitant procedure, had respi-
ratory dysfunction and elevation of Fontan pressure on
postoperative day 2. The patient was supported with ECMO
for 5 days and successfully weaned after fenestration. No sig-
nificant difference was observed between the groups with
regard to the duration of ventilator support, pleural drainage,
and peritoneal drainage. The number of patients requiring
prolonged pleural drainage for more than14 days was not
TABLE 2. Previous procedures
Previous procedures Group S Group L
None 2 1
C-P anastomosis
SVC-PA anastomosis 23 22
Other 1 0
Hemi-Fontan 0 1
Kawashima 0 1
Intrapulmonary artery septation 6 8
None 6 4
AV valve repair 11 11
Pulmonary artery plasty 23 27
Pulmonary artery banding 9 16
Atrial septectomy 8 3
DKS anastomosis 4 2
Modified Norwood 13 3
RV-PA conduit 9 2
AP shunt 4 1
AP shunt 22 35
VP shunt 0 5
TAPVC repair 4 2
Coarctation repair 2 7
Pacemaker implantation 1 1
Pulmonary vein stenosis repair 5 7
Starnes operation 0 1
Diaphragm plication 0 1
MAPCA unifocalization 0 1
Aortic valve repair 0 1
Aortic valve replacement 0 1
AV valve replacement 0 1
LV volume reduction surgery 0 1
C-P, Cavopulmonary; SVC, superior vena cava; PA, pulmonary artery; AV,
atrioventricular; DKS, Damus–Kaye–Stansel; AP, aortopulmonary; VP, ven-
tricular–pulmonary; TAPVC, total anomalous pulmonary venous connection;
MAPCA, major aortopulmonary collateral arteries; LV, left ventricle.acic and Cardiovascular Surgery c Volume 135, Number 5 1147
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DTABLE 3. Operative data
Group S n Group L n P value
Mean CPB time (min) 147 6 54 167 6 53 .09
Median 136 (67–282) 162 (80–303)
Aortic crossclamping, n (%) 17 (47%) 24 (67%) .38
Time (min) 58 6 26 17 69 6 35 24 .3
Median 62 (9–118) 63 (10–134)
Fenstration, n (%) 3 (8%) 2 (6%) .67
Mean graft size 17.0 6 1.3 17.9 6 1.9 .03*
Median 16 (16–20) 18 (14–20)
Concomitant procedures
Intracardiac 8 11 .38
AV valve repair 2 4
ASD enlargement 3 3
AV valve replacement 1 0
PVO repair 0 2
DKS anastomosis 0 1
SAS resection 0 1
PAPVC repair 1 0
PA–LA fistula closure 1 0
Extracardiac 9 13 .46
PA plasty 6 8
Main PA division 0 3
Pacemaker implantation 1 2
Other 2
CPB, Cardiopulmonary bypass; AV, atrioventricular; ASD, atrial septal defect; PVO, pulmonary vein obstruction; DKS, Damus–Kaye–Stansel; SAS, subaortic
stenosis; PAPVC, partial anomalous pulmonary vein connection; PA, pulmonary artery; LA, left atrium. *P , .05 indicates significant P value.different between the groups (group S vs group L: 6 vs 5; P5
.76). However, the median duration of stay in the intensive
care unit was significantly longer for group S patients than
for group L patients (group S vs L: 7 days vs 4 days; P 5
0.01), and the average volume of peritoneal drainage was sig-
nificantly greater in group S than in group L (group S vs group
Figure 1. Distribution of the size of extracardiac conduit in 72 pa-
tients for each year. The left bar indicates cases in group S and the
right bar, in group L. The dotted bar indicates a 14-mm diameter
conduit; white bar, a 16-mm diameter conduit; black bar, an
18-mm diameter conduit; and gray bar, a 20-mm diameter conduit.
Since 2002, use of 18-mm diameter conduits has increased.1148 The Journal of Thoracic and Cardiovascular Surgery c MaL: 26.16 15.1 mL $ kg $ d21 vs 14.16 10.2 mL $ kg $ d21;
P5 .0007) (Table 4). With regard to the prevalence of supra-
ventricular dysrhythmia, 7 patients in group S and 9 patients
in group L had supraventricular tachyarrhythmia. Three
patients in both groups had sinus dysfunction. There was no
difference in the prevalence of supraventricular dysrhythmia
between the 2 groups.
Follow-up
Follow-up was complete in all patients. Median follow-up
periods were 29.2 (1.7–79.7) and 42.1 (2.8–94.2) months
for groups S and L, respectively. Two group S patients
with hypoplastic left heart and heterotaxy syndrome died of
respiratory infection. The 5-year actuarial survival was
91% for group S and 97% for group L (P 5 .3, Figure 2).
Protein-losing enteropathy developed in 3 patients (2 in
group S and 1 in group L). All patients are currently respond-
ing to medical treatment. Postoperatively, no thromboem-
bolic events occurred, and no patient required conduit
replacement for obstruction. With regard to the prevalence
of supraventricular dysrhythmia, patients with sick sinus syn-
drome, and grade I atrioventricular block, 1 in each group
were treated with a pacemaker to maintain better synchronic-
ity between the atrial and ventricular contractions. Only 1
patient with heterotaxy syndrome in group S had supraven-
tricular tachyarrhythmia even though the patient wasy 2008
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Group S n Group L n P value
ICU stay, median (d) excluding death 7 (1–45) 35 4 (1–14) 35 .01*
Hospital stay, median (d) excluding death 31 (13–85) 35 28 (17–143) 35 .53
Duration of ventilator support, median (h) 11 (3–1119) 35 7 (3–1385) 35 .41
Duration of pleural drainage, median (d) 9 (5–27) 34 9 (5–19) 34 .69
Volume of pleural drainage, mean (mL $ kg $ d21) 12.6 6 9.6 10.5 6 6.3 .70
Prolonged pleural drainage .14 days (cases) 6 (16.7%) 5 (14.7%) .78
Duration of peritoneal drainage, median (d) 8 (3–19) 33 7 (2–35) 33 .68
Volume of peritoneal drainage, mean (mL $ kg $ d21) 26.1 6 15.1 14.1 6 10.2 .0007*
Prolonged peritoneal drainage .14 days (cases) 2 (6.1%) 3 (9.1%) .67
ICU, intensive care unit. *P , .05, indicates significant P value.CH
Dadministered amiodarone prophylactically. One patient in
group L was administered isoproterenol owing to atrioven-
tricular dissociation. With regard to fenestration, 1 patient
who underwent fenestration in group S died of respiratory in-
fection as previously mentioned. We confirmed spontaneous
closure of the fenestration in 2 patients in group L. The other
two fenestrations were left open.
Follow-up Catheterization Data
We performed postoperative follow-up catheterization in 30
group S and 32 group L patients. The mean interval between
the ECFP and follow-up was 9.8 6 3.8 months for group S
and 13.1 6 4.2 months in group L. There was a significant
difference between these 2 periods (P 5 .002).
No difference was observed between the groups with re-
gard to IVC pressure, intraconduit pressure, superior vena
cava pressure, bilateral pulmonary artery pressure, pulmo-
nary capillary wedge pressure, pulmonary artery resistance,
ejection fraction, cardiac index, and room air saturation
(Table 5). There was a pressure gradient between precavopul-
monary and postcavopulmonary anastomosis and there was
also a statistically significant difference between the intra-
Figure 2. Kaplan–Meier survival in 72 patients undergoing the
ECFP. The number of patients at risk is indicated above the hori-
zontal axis. There is no difference of survival between patients
in groups S and L.The Journal of Thorconduit pressure and the right and left pulmonary artery pres-
sures; however, no pressure gradient had developed between
the IVC and conduit.
Discussion
Since the introduction of the concept of total cavopulmonary
connection,7 the outcome of the Fontan completion has im-
proved dramatically. Currently, the ECFP and LTFP are the
two favored approaches for Fontan completion. However,
the use of ECFP may be disadvantageous because of the use
of an artificial graft that lacks growth potential and requires an-
ticoagulation therapy to prevent thromboembolic events.9,11
Generally, ECFP is performed in patients weighing more
than15 kg so that an adult-sized conduit (generally 20 mm
in diameter) can be used . Therefore, the patient age required
for the ECFP is higher than that required for the LTFP.2-4 The
data on the LTFP12 revealed that age at the time of operation
was not a limiting factor for Fontan completion.
To eliminate cyanosis as early in life as possible, we per-
formed the ECFP in patients who were approximately 1 year
old and weighed less than10 kg. The operative mortality of
the entire cohort of patients in this series was approximately
3%. This is similar to that reported in previous studies.2,6,13,14
Numerous perioperative risk factors are associated with in-
creased mortality after the ECFP. These include pulmonary
artery resistance, pulmonary artery size, hypoplastic left heart
syndrome, and heterotaxy syndrome. A direct comparison of
the preoperative features of both patient groups revealed no
differences in this study. In terms of morphologic features,
especially, half of the patients in both the groups had hypo-
plastic left heart or heterotaxy syndrome. Moreover, pulmo-
nary vascular resistance and Nakata index did not differ
between the groups. Under well-controlled hemodynamic
conditions for Fontan completion, the somatic size of patients
might not be a limiting factor for performing the ECFP, even
in patients weighing less than10 kg.
However, for performing ECFP in patients with low body
weight, the size of the conduit, which lacks growth potential,
might pose difficulties in the future.9,11 The main problemacic and Cardiovascular Surgery c Volume 135, Number 5 1149
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DTABLE 5. Postoperative catheterization data
Group S n Group L n P value
Mean interval after ECFP (mo) 9.8 6 3.8 30 13.1 6 4.2 32 .002*
SVC pressure, mean (mm Hg) 12.4 6 2.4 27 12.4 6 2.2 29 .94
Right PA pressure, mean (mm Hg) 11.0 6 2.7y 26 11.1 6 2.7y 26 .72
Left PA pressure, mean (mm Hg) 11.0 6 2.6y 26 10.9 6 2.7y 29 .92
Intraconduit pressure, mean (mm Hg) 12.5 6 2.3 21 12.2 6 2.2 22 .62
IVC pressure, mean (mm Hg) 12.4 6 2.2 28 12.4 6 2.1 28 .73
PCW pressure, mean (mm Hg) 6 6 2 29 6 6 3 32 .81
Rp (Wood units) 1.7 6 1.0 28 1.5 6 1.0 29 .38
Ejection fraction (%) 54 6 11 28 58 6 10 32 .15
Cardiac index (L/min/m2) 3.0 6 0.5 28 3.2 6 1.1 31 .53
Room air saturation (%) 93 6 4 28 95 6 1 32 .73
ECFP, Extracardiac conduit Fontan procedure; SVC, superior vena cava; PA, pulmonary artery; IVC, inferior vena cava; PCW, pulmonary capillary wedge; Rp,
resistance of pulmonary artery. *P , .05 significant P value. yP , .05 significant P value; PA pressure versus SVC pressure, IVC pressure, and intraconduit
pressure.concerning ECFP is the risk of late conduit obstruction. Amo-
deo and colleagues15 have reported a mean reduction of the
internal conduit diameter of 18% during the first 6 months
with no further progression over the following 5 years. Mar-
celletti, Iorio, and Abella11 from the same study group re-
ported that they had never used a conduit less than 16 mm
in diameter in their initial series. However, no cases of
PTFE conduit replacement owing to obstruction were re-
ported in the longest follow-up series. There have been nu-
merous reports regarding the benefits of ECFP; however, no
reports of conduit replacement owing to size mismatch
affecting somatic development have been reported. Nakao
and colleagues16 have assessed the size of the IVC by means
of echocardiography. In their study, mean diameters of the
IVC were changed 17 mm in the left lateral position to 23
mm in the right lateral position in patients with right atrial
pressures greater than 8 mm Hg. The study might suggest
that a conduit 18 or 20 mm in diameter might be acceptable
in adults. Initially, we used a conduit 16 mm in diameter;
however, after gaining experience, we have recently in-
creased the use of 18-mmdiameter conduits.We administered
5mg/kg of ticlopidine as antiplatelet therapy.We have not en-
countered any cases of conduit obstruction thus far; however,
further studies are necessary for evaluating the fate of artificial
tube grafts, particularly those less than 16 mm in diameter.
Persistent pleural effusion is one of the significant causes
ofmorbidity in the postoperative period after ECFP.17Gaynor
and colleagues13 reported that fenestration andmodified ultra-
filtration are associatedwith a decrease in the duration of pleu-
ral effusions. In this series, we used modified ultrafiltration in
all patients. Patients with fenestrations had to have cyanosis
for a longer duration and had to undergo another intervention
to close the fenestration. Therefore, we did not use fenestra-
tions except in patients with a high Fontan pressure greater
than 18 mm Hg. Only 5 (7%) of 72 patients in this series
required fenestration. An alternative approach to reduce pleu-1150 The Journal of Thoracic and Cardiovascular Surgery c Mral effusion might be to minimize the use of cardiopulmonary
bypass, thereby reducing the activation of inflammatory
mediators.6 If most of the mediastinal dissection is performed
off-pump and no intracardiac procedures are necessary, then
the average cardiopulmonary bypass time required for the
superior and inferior anastomoses should be considerably
decreased.
In this study, no difference in the duration of pleural drain-
age was noted between the groups. We speculated that peri-
toneal drainage might be helpful to reduce duration and
volume of pleural drainage. Mainwaring, Lamberti, and Hu-
gli18 reported an increase in the concentration of the activated
complement C3 and interleukin 6 after the ECFP. Bokesch
and colleagues19 reported a high concentration of proinflama-
tory cytokines in the peritoneal fluid. They suggested that
peritoneal fluid may serve as a depot for harmful inflamma-
tory cytokines after cardiopulmonary bypass, and removal
of the peritoneal fluid could lower serum concentrations.
No difference was observed between the groups with re-
gard to duration of peritoneal drainage and number of patients
with prolonged peritoneal drainage; however, the peritoneal
fluid drainage volume was higher in group S than in group
L. In addition, cardiopulmonary bypass time was shorter in
group S than in group L. No specific reason was found for
the prolonged intensive care unit stay of group S as compared
to group L. We speculated that the large volume of peritoneal
drainage might require extensive fluid replacement to stabi-
lize hemodynamics. We recognized that the hospital stay
was considerably longer than that mentioned in any other pre-
viously published reports. Japan’s lenient health insurance
system might account for this.
This study has several limitations. It is a retrospective and
nonrandomized study. There is a lack of reports on peritoneal
drainage after the ECFP, and only a few patients in this study
were operated on without peritoneal drainage. Therefore, it is
very difficult to rule out any influence of peritoneal drainageay 2008
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Don the postoperative course. In particular, the follow-up
period in group S patients was relatively short inasmuch as
they were growing; therefore, the inference regarding free-
dom from conduit obstruction and the need for reoperation
in relation to outgrowth is uncertain. Further, a long-term fol-
low-up study is essential.
In conclusion, we evaluated the technical feasibility of
ECFP in patients weighing less than 10 kg. In terms of mor-
tality and midterm results, the outcome of ECFP was accept-
able in patients who weighed less than 10 kg. Currently, it
may not be possible to consider ECFP as the standard proce-
dure in patients weighing less than 10 kg. However, the pro-
cedure may be feasible in patients who, for instance, have
severe cyanosis owing to pulmonary arteriovenous malfor-
mation. Further studies are required to assess the late hemo-
dynamics of patients with small conduits when they achieve
full somatic growth and the long-term outcome of these small
conduits.
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Discussion
Dr Ed Petrossian (Madera, Calif). Dr Ikai, I enjoyed your presen-
tation. I will make a comment on the paper inasmuch as I believe it is
an important subject, and I have 3 questions for you. The comment
will be primarily focused on the issue of putting in small conduits in
small patients.
In this study, you and your colleagues have shown that the ECFP
can be performed with excellent perioperative and midterm out-
comes in patients less than 2 years of age and less than 10 kg in
weight. At a median follow-up time of 29 months, there were no
thromboembolic events and none of the patients required conduit re-
placement owing to obstruction. I believe this is an important and
timely paper because it brings into light the concerns and controver-
sies about the timing of this operation with respect to age, weight,
and the related issue of conduit size. Regarding the choice of conduit
size, this decision is influenced by two competing factors. The first is
the desire to insert a large conduit to avoid growth-related obstruc-
tion. Ideally, the conduit should match or slightly exceed the size of
an average adult IVC at the level of the diaphragm. The second is the
desire to avoid extremes of IVC–conduit mismatch. Significant mis-
match can lead to turbulence, energy loss, stasis, and thrombosis. In-
formation on the average size of the adult IVC at the level of the
diaphragm is limited. Most studies instead report the size of the in-
frahepatic or most commonly the infrarenal IVC. Accuracy of the
studies is affected by the fact that the IVC is an extremely compliant
vessel so that its diameter and shape vary greatly with a number of
factors, including patient body position, volume status, systemic ve-
nous pressure, phase of respiration, and to a lesser extent phase of
the cardiac cycle. In adults, the size of the IVC does not correlate
with age, height, weight, or body surface area. Therefore, prediction
of a patient’s future IVC diameter based on projections of the pa-
tient’s future height, weight, or body surface area as an adult may
be inaccurate.
The most consistent finding of the IVC diameter is that it corre-
lates well with right-sided systemic venous pressures. Patients with
elevated pressures have been shown to have significantly dilated
IVCs. It therefore follows that an adult patient with a Fontan circu-
lation and an inherently elevated systemic venous pressure will be
expected to have a dilated IVC. The available data on IVC diametercic and Cardiovascular Surgery c Volume 135, Number 5 1151
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Dbased on angiography, computed tomographic scan, and echocar-
diographic studies suggest that the average normal IVC diameter
ranges from 20 to 28 mm with significant interstudy variability. In
patients with elevated systemic venous pressures, the average diam-
eter is about 30 mm. These data suggest that most conduits, espe-
cially those less than 18 or 20 mm, eventually will need to be
replaced. It appears, therefore, that a protocol of using small con-
duits in patients less than 10 kg in weight will likely lead to signif-
icant conduit obstruction and the need for early reoperation. One
option, of course, is to routinely use 20-mm conduits in these small
patients. Although you did not report any case of thromboembolism,
we believe that insertion of markedly oversized conduits is not an
optimal solution either, inasmuch as it can cause significant IVC–
conduit size mismatch and related complications.
I have 3 questions for you. First, what size mismatch between the
IVC and the conduit are you comfortable with at the time of the op-
eration? In other words, when you are trying to decide what size con-
duit to insert at the time of the operation, how much larger can the
conduit be compared with the size of the IVC?
Dr Ikai. Thank you, Dr Petrossian, for your comments and the
question. Size mismatch between the IVC and the conduit may
not be so big an issue. We have not measured the size of the IVC
during the operation because we can cut the IVC not on the IVC it-
self. Maybe sometimes we can make the incision line to the right
atrium and maybe the IVC tissue has included some right atrial tis-
sue. That means that these tissues are very flexible and sometimes
we can put a much larger conduit on that. Maybe a problem has hap-
pened with size mismatch between the pulmonary artery to the con-
duit. Another big issue is if we insert too large a conduit, pulmonary
vein obstruction may result. We think that in a baby weighing less
than 10 kg, an18 mm in diameter conduit is suitable. In a baby
less than 20 kg, maybe a 20 mm in diameter conduit is suitable.
Dr Petrossian. I agree with you. We also use a cuff of atrium to
anastomose to the conduit and not the IVC itself so that we can put in
a larger conduit, and the conduit is almost always larger than the
IVC; however, there is a limit to that. In our experience, and I think
this is corroborated by others, we try to avoid upsizing the conduit
by more than 25% compared with the size of the IVC to avoid a sud-
den change in vessel caliber going from the IVC to the conduit. This
discrepancy has been demonstrated to cause a lot of turbulence,
energy loss, stasis, and thrombosis.
My second question is, since your patients less than 10 kg are at
risk for outgrowing their conduits, how do you plan on monitoring
them? In other words, what diagnostic modalities do you use to look
for conduit obstruction as these patients grow?
Dr Ikai. I showed the postoperative angiogram in the presenta-
tion. We routinely perform angiography a year after the operation.
At that time, if the conduit shows some obstruction, it may be a prob-
lem, but so far we have not seen any obstruction on the angiogram. If
the patient needs more follow-up, we use a computed tomographic
angiogram or a magnetic resonance angiogram because they are less
invasive measures.
Dr Petrossian. In our experience with more than 360 Fontan pa-
tients, we have been primarily monitoring them with echocardio-
grams, but I agree with you that as these patients grow and
become more at risk for conduit obstruction, more accurate imaging
modalities are going to be necessary. Magnetic resonance imaging,1152 The Journal of Thoracic and Cardiovascular Surgery c Mcomputed tomography, and probably also cardiac catheterization
may be needed to measure the gradient across these conduits.
My third and last question is, what will be your criteria for
reoperation for conduit obstruction in asymptomatic patients?
We all agree that symptomatic patients will need conduit replace-
ment, but at what point and with what diagnostic findings will
you be comfortable with replacing a conduit in an asymptomatic
patient?
Dr Ikai. It is very difficult to change the conduit in an asymp-
tomatic patient. However, if there is a pressure gradient between
the IVC and the conduit at catheterization, we may have to do the
operation. During catheterization, with the patient in the resting po-
sition, the data, the pressure number, may not be accurate, so we
probably will have to do an exercise test for these patients and get
some exercise tolerance. If these numbers become low, that may
indicate that the conduit should be changed.
Dr Petrossian. I agree that exercise testing may be one way to
determine when it is time for conduit replacement. Imaging modal-
ities may not be sufficient. These IVCs will eventually dilate be-
cause they are very compliant vessels. The fact that they become
very large does not necessarily mean that they are obstructed. In ad-
dition, collaterals will develop, just as with the SVC, in patients with
bidirectional Glenn shunts, so it will be difficult to figure out when it
is time to replace the conduit. However, I think if at cardiac cathe-
terization there is any gradient, even a small amount of gradient
between the conduit and a dilated IVC in combination with an
abnormal exercise test, then it will be time to proceed with conduit
replacement even if the patient is asymptomatic.
Dr Ikai. In terms of reoperation, when we started this strategy,
we were still thinking about this Fontan procedure as a palliative
procedure because we did not have any long-term result with this
small conduit. Now, because of the good result of the Fontan con-
version from the classic Fontan to the total cavopulmonary connec-
tion, we think the operation itself is not so risky, especially in
a patient who has an established Fontan circulation.
Dr Petrossian. I certainly I agree with that. When the patients
return to have the conduit replaced, it is not as big an operation or
as risky as the first primary Fontan.
Dr Winfield Wells (Los Angeles, Calif). My question is pretty
simple. Why do this? What are the advantages? Your 2 groups
came out the same. The saturations are the same in the longer-
term follow-up. They seemed to have the same saturations when
you did them, so why not wait? What are the advantages of doing
this operation in a patient weighing less than 10 kg?
Dr Ikai.We believe that the final goal of the Fontan operation is
elimination of cyanosis, and in these 2 groups the big difference is
not only the body weight but also the age. We did this operation
at around a year of age. If we wait until patients become 15 kg,
we may have to wait until the baby becomes 2 or 3 years old. Wait-
ing these 1 or 2 years may not be good for the patient. In these 2
years the patient’s activity is increasing. Maybe the child starts
walking and running. This quality we think is very important. We
want to eliminate cyanosis. That is our reason to do this operation.
Dr Wells. Do you have any evidence for that?
Dr Ikai. We have not published yet, but when we do this oper-
ation at the younger age, some children catch up soon. This is
another reason to do this operation early.ay 2008
